XML 30 R21.htm IDEA: XBRL DOCUMENT v3.26.1
Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
Segment
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Description Of Business [Line Items]      
Net Income (Loss) $ (10,791) $ (14,880)  
Accumulated deficit (616,955)   $ (606,164)
Cash, cash equivalents, available-for-sale investments and restricted cash 68,300    
Restricted cash $ 1,805 $ 2,432 $ 2,235
Number of operating segment | Segment 1    
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Our CODM is our Chief Executive Officer, who reviews and evaluates consolidated research and development expenses, general and administrative expenses, net loss, net cash used in operating activities and our consolidated cash and cash equivalents for purposes of making operating decisions, allocating resources and planning and forecasting future periods.    
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] srt:ChiefExecutiveOfficerMember    
Pangu BioPharma [Member] | Hong Kong [Member]      
Description Of Business [Line Items]      
Majority-owned subsidiary percentage 98.00%